CGX-926 / Congruence Therapeutics - LARVOL DELTA

Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity (PRNewswire) - "The first-in-human Phase 1/1b study is designed to evaluate the safety, tolerability, and pharmacokinetics of CGX-926, while also exploring preliminary efficacy in individuals with MC4R-deficient obesity....Congruence Therapeutics expects data to emerge from the Phase 1/1b program in the first half of 2027."

First-in-human • P1 data • Trial status • Obesity

CGX-926, a Melanocortin 4 Receptor Corrector for Early-Onset Obesity in MC4R Deficient Patients (OBESITY WEEK 2025) - "These preclinical data collectively show that CGX-926 corrects MC4R deficiency in vitro and in vivo. CGX-926 has the potential to be the first targeted orally bioavailable small molecule MC4R pharmacological corrector that addresses the root cause of genetic obesity in patients with MC4R deficiency."

Clinical • Genetic Disorders • Obesity • MC4R

Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025 (PRNewswire) - "Preclinical data on CGX-926, a first-in-class MC4R corrector, demonstrate that this small molecule restores MC4R expression and signaling across a spectrum of clinically relevant receptor variants. In a proprietary murine model of MC4R-deficient obesity, CGX-926 significantly reduced body-weight gain, fat mass, and hyperphagia while preserving lean mass....'We are excited to advance CGX-926 to Phase 1 studies in early 2026'...."

New P1 trial • Preclinical • Obesity